3SBio Q1 Net Revenue Increases
3SBio posted a net income of RMB26.65m, or RMB0.17 per diluted share, compared to RMB15.88m, or RMB0.11 per diluted share, for the prior year period. Income from operations
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.